News

Plegridy is an investigational subcutaneous injectable therapy for RRMS, in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body. The positive

The three-period randomized, double-blind, three-period, parallel group, placebo-controlled Phase III trial showed that tofacitinib, as a 5mg or 10mg pill taken twice daily, met its two primary efficacy

The two firms said they are committed to the Nerventra clinical development program for multiple sclerosis (MS) and are focused on evaluating the CHMP feedback to determine potential

According to the company the dose counter is designed to help asthma patients, as well as their caregivers to keep track of the number of doses remaining in

The facility is located approximately 100 miles outside of Toronto. This facility is where production will commence after installation of the required security measures and subsequent receipt of

Dr Craig McDonald, Professor of Physical Medicine and Rehabilitation at the University of California, Davis, who developed and validated the six-minute walk test as a primary clinical endpoint

This application protects the method of composition and method of use of Prima’s CVac for the generation of a cytotoxic T cell response against the mucin 1 antigen.

The novel cancer vaccine is specifically formulated to target the blood vessels that supply the tumor through induction of tumor autoimmunity and immune stimulation. Batu Biologics scientific research

SYNRIBO is a treatment for adults with chronic myeloid leukemia (CML) who are no longer responding to or are unable to tolerate two or more tyrosine kinase inhibitors